Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer

开发用于治疗晚期乳腺癌的原癌基因 PELP1 强效抑制剂

基本信息

项目摘要

Project summary Breast cancer (BCa) is the second leading cause of cancer death in women. Among Servicewomen, BCa is the most commonly diagnosed cancer, accounting for 30% of female cancers with increased prevalence in older Veterans. BCa has distinct molecular subtypes; estrogen receptor (ER) positive and triple negative breast cancer (TNBC). A significant portion of ER-positive BCa initially respond to anti-estrogens or aromatase inhibitors but eventually exhibit unresponsiveness to therapy, develop therapy-resistant breast cancer (TR-BC), and ultimately progress to incurable metastasis. Moreover, TNBC has a more aggressive clinical course and overall lack of targeted therapies. Development of effective therapies for female Veterans with TR-BC or TNBC represents the highest unmet need in breast cancer treatment. Our ongoing research on PELP1, an oncogenic coregulator protein originally cloned in this lab, displays an integral role in multiple nuclear receptor (NR) functions associated with BCa progression. PELP1 expression is commonly dysregulated in BCa eliciting a conducive environment for epigenetic modifications. Concomitantly, PELP1 is a prognostic indicator for poorer BCa survival and indicator of therapy resistance and metastases. We have developed a first-in-class small molecule inhibitor of PELP1 (SMIP) displaying effectivity against TR-BC and TNBC. SMIPs block PELP1’s ability to promote epigenetic modifications. The objective of this proposal is to further develop a lead SMIP into a novel drug for the clinical treatment of TR-BC and TNBC. Our overarching hypothesis is that PELP1 couples NRs with epigenetic modifiers; therefore, targeting the PELP1 axis with SMIPs will have a therapeutic utility in treating both TR-BC and TNBC. In Aim 1, we will determine lead SMIPs mechanism of action using biochemical, molecular, unbiased mass spectroscopy, and whole genome sequencing approaches. In Aim 2, we will optimize SMIP derivatives and conduct studies establishing the maximum tolerated dose and dose efficacy in vivo using TR-BC and TNBC models. In Aim 3, we will test the translatability of optimized SMIPs using therapy resistant xenografts, metastatic models, and patient derived xenografts (PDX). This proposal is innovative as SMIPs block signaling from multiple oncogenic PELP1 activated NRs to uniquely promote repression of epigenetic modifiers. Successful completion of the proposed work will result in the development of a first-in-class cancer therapy drug specifically addressing the current lack of TR-BC and TNBC targeted therapies. This research program is significant as it is expected to aid in identifying therapeutic targets critical to the treatment and prevention of advanced breast cancer in the population of Servicewomen.
项目概要 乳腺癌(BCa)是女性癌症死亡的第二大原因。在女军人中,BCa 是 最常诊断出的癌症,占女性癌症的 30%,且在老年人中患病率更高 退伍军人。 BCa 具有不同的分子亚型;雌激素受体 (ER) 阳性和三阴性乳房 癌症(TNBC)。很大一部分 ER 阳性 BCa 最初对抗雌激素或芳香酶抑制剂有反应 但最终表现出对治疗无反应,发展为治疗抵抗性乳腺癌(TR-BC),并且 最终进展为无法治愈的转移。此外,TNBC 具有更具侵略性的临床过程,总体而言 缺乏针对性治疗。为患有 TR-BC 或 TNBC 的女性退伍军人开发有效疗法 代表了乳腺癌治疗中未满足的最高需求。我们正在进行的关于 PELP1(一种致癌物质)的研究 核心调节蛋白最初在本实验室克隆,在多核受体 (NR) 中发挥着不可或缺的作用 与 BCa 进展相关的功能。 PELP1 表达在 BCa 中通常失调,引发 有利于表观遗传修饰的环境。同时,PELP1 是较差的预后指标 BCa 存活率以及治疗抵抗和转移的指标。我们开发了一流的小型 PELP1 (SMIP) 分子抑制剂对 TR-BC 和 TNBC 有效。 SMIP 阻止 PELP1 的能力 促进表观遗传修饰。该提案的目标是将领先的 SMIP 进一步发展为新颖的 临床治疗TR-BC和TNBC的药物。我们的首要假设是 PELP1 与 NR 结合 具有表观遗传修饰剂;因此,用 SMIP 靶向 PELP1 轴将在治疗中具有治疗效用 TR-BC 和 TNBC。在目标 1 中,我们将使用生化、 分子、无偏质谱和全基因组测序方法。在目标2中,我们将优化 SMIP 衍生物并进行研究,确定最大耐受剂量和体内剂量功效 TR-BC 和 TNBC 型号。在目标 3 中,我们将使用抗治疗测试优化 SMIP 的可翻译性 异种移植物、转移模型和患者来源的异种移植物(PDX)。该提案具有创新性,因为 SMIP 阻止了 来自多个致癌 PELP1 激活 NR 的信号传导能够独特地促进表观遗传修饰因子的抑制。 成功完成拟议工作将开发出一流的癌症疗法 该药物专门解决了目前缺乏TR-BC和TNBC靶向治疗的问题。该研究计划是 意义重大,因为它有望帮助确定对治疗和预防至关重要的治疗靶点 女军人群体中的晚期乳腺癌。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ratna K Vadlamudi其他文献

Ratna K Vadlamudi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ratna K Vadlamudi', 18)}}的其他基金

Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer
开发用于治疗晚期乳腺癌的原癌基因 PELP1 强效抑制剂
  • 批准号:
    10044416
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Development of Potent Inhibitors of proto-oncogene PELP1 for Treating Advanced Breast Cancer
开发用于治疗晚期乳腺癌的原癌基因 PELP1 强效抑制剂
  • 批准号:
    10516093
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    7252323
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    7119986
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    8608682
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    7209920
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    8211872
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    6933178
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    6791280
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:
PELP1, a Novel Regulator of Estrogen Receptor
PELP1,一种新型雌激素受体调节剂
  • 批准号:
    6687074
  • 财政年份:
    2003
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Standard Grant
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了